即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 2245053-57-8 | 货号 | BCP46430 |
中文名 | Etavopivat | ||
英文名 | Etavopivat | ||
中文别名 | |||
英文别名 | FT-4202;FT 4202;FT4202; | ||
SMILES | C1COC2=C(O1)C=C(C=N2)S(=O)(=O)N3CC4=C(C3)CN(C4)C(=O)C(CO)C5=CC=CC=C5 | ||
化学名称 | |||
分子式 | C22H23N3O6S | 分子量 | 457.5 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Etavopivat is an orally available, small-molecule allosteric activator of the selective red blood cell (RBC) isoform of pyruvate kinase (PK-R), with potential to improve symptoms in sickly cell disease (SCD) patients. Upon oral administration, etavopivat allosterically binds to and activates PK-R, thereby enhancing the glycolytic pathway activity in RBCs. This improves adenosine triphosphate (ATP) levels and reduces 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs. This results in increased oxygen affinity, improved RBC deformability, decreased sickle RBC hemolysis, increased hemoglobin (Hb) levels and improved RBC membrane function. Mutations in PK-R cause deficiency in PK-R which prevents adequate RBC glycolysis, leading to a buildup of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PK-R product ATP. |
Tags:Etavopivat 供应商,Etavopivat 购买,Etavopivat 生产,Etavopivat 批量,Etavopivat 供应,Etavopivat 订购,Etavopivat 采购